Nautilus Biotechnology to Research Further on Untapped Potential of the Human Proteome

Nautilus Biotechnology, the most renowned single-molecule protein analysis platform for quantifying the proteome, in a recent announcement, has stated that the completion of its business combination with Arya Sciences Acquisition Corp III, which is a special purpose acquisition company (SPAC) sponsored by Perceptive Advisors. Both the companies will commence trading shares of their common stock under the ticker symbol "NAUT" by June.

Nautilus is developing a brand new protein analysis platform aiming to identify more than 95 percent of the proteome. The company is integrated with breakthrough innovations in the field of computer science, engineering, and biochemistry. The Nautilus Proteomic Analysis Platform is architecture to leverage different proteome-relation solutions such as nanofabricated, large-scale, single-molecule protein array, multi-cycle imaging, and machine learning analysis which helps in measuring the proteome with extreme sensitivity and scale.

Nautilus has reimagined how to analyze and quantify the proteome comprehensively. The company is also seeking to create a new gold standard in proteomics that will create positive impacts on human health. The company's technology will change the scale of what is possible in proteomics to enable significant advancements in drug discovery and development and help revolutionize the biomedical research sector.